Target intelligence / Profile preview

Pygopus family PHD finger 2 (PYGO2)

Target
PYGO2
Molecular classification
Chromatin-binding protein, Transcription co-activator, Epigenetic regulator, Nuclear protein
01

Overview

Pygopus family PHD finger 2 (PYGO2) is a nuclear chromatin effector protein and transcription co-activator that plays an essential role in the Wnt/β-catenin signaling pathway by facilitating the transcription of Wnt target genes. PYGO2 contains a conserved PHD (plant homeodomain) finger, uniquely capable of binding both methylated histone H3 (notably H3K4me2/3) and the co-factors BCL9/B9L, linking chromatin modification states to transcriptional activation complexes. Widely expressed during embryogenesis with higher abundance in tissues undergoing rapid development, PYGO2 is required for normal organogenesis, lens development, and kidney morphogenesis in mammals. Overexpression and dysregulation of PYGO2 are associated with cancer progression and poor prognosis, especially in gliomas and hormone-refractory prostate cancer, making it a potential biomarker and therapeutic target. Therapeutic modulation is challenging due to its role as a broad epigenetic regulator influencing numerous gene programs in both normal and malignant contexts.

Other names
Pygopus homolog 2PP79101190004M21Rikpygopus 2PYGO2
02

Mechanism of action

Targeted inhibition of chromatin binding or protein-protein interaction domains (e.g., PHD finger disruption) and modulation of Wnt/β-catenin pathway activity.

03

Biological functions

Regulation of Wnt/β-catenin signaling pathwayTranscriptional activation of Wnt target genesChromatin modification (recognizes H3K4me2/3 marks)Modulation of embryonic development and organogenesisCell proliferationEpigenetic regulation in cancer
04

Disease associations

Cancer (notably glioma and prostate cancer)Embryonic developmental disordersPotential involvement in castration-resistant prostate cancer
05

Safety considerations

Epigenetic regulators with broad transcriptional roles can have pleiotropic effects and safety risks, including impact on normal tissue development and stem cell renewalPotential toxicity from systemic inhibition due to importance in tissue homeostasis and organogenesis
06

Interacting drugs

No clinically approved drugs directly targeting PYGO2 are reported in current databases or primary literature searches. However, preclinical studies are investigating epigenetic or transcriptional pathway inhibitors as potential modulators.
07

Biomarkers

PYGO2 overexpression as a prognostic biomarker in gliomaPossible biomarker in aggressive or castration-resistant prostate cancer

Beyond the preview

Go deeper on Pygopus family PHD finger 2 (PYGO2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pygopus family PHD finger 2 (PYGO2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call